Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The efficacy of botulinum toxin A (BoNT) in alleviating motor symptoms of cervical dystonia (CD) has been well established, and it is the treatment of choice in this disease. Lately, the effect of BoNT on non-motor symptoms (NMS) such as cognitive function, depression, anxiety, pain, and sleep disturbance has been observed in patients with CD. A comprehensive clinical and functional assessment of motor (dystonia severity, gait) and non-motor symptoms (cognitive functions, depression, anxiety, sleep, and pain) has been performed in a total of 34 adult patients with cervical dystonia before and after BoNT treatment. Results have also been compared to a control group. Significant improvements in the scales assessing dystonia severity have been observed, which is in line with previous studies on the effect of BoNT on motor symptoms in dystonia. Interestingly, the results also clearly indicate that BoNT has a positive effect on NMS. Among the studied non-motor domains, depression and cognitive functions improved the most after the treatment procedure. The study highlights the potential of BoNT to positively influence non-motor symptoms in patients with cervical dystonia, although its effect on various NMS is not equal.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390245 | PMC |
| http://dx.doi.org/10.3390/toxins17080396 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Abnormal Connectivity of the Head Neural Integrator in Cervical Dystonia.
Mov Disord
September 2025
Movement Investigation and Therapeutics Team, Sorbonne Université, INSERM U1127, CNRS UMR 7225, Paris Brain Institute, Paris, France.
Background: Cervical dystonia is characterized by abnormal neck and head movements, possibly related to a dysfunction of the interstitial nucleus of Cajal (INC) and the head neural integrator, a system responsible for the control of head and eye movements. However, neuroanatomical evidence of alterations in the head neural integrator in cervical dystonia is sparse.
Objectives: We investigated structural and functional integrity of the INC and its connections in cervical dystonia.
Pain localization and response to botulinum toxin in cervical dystonia.
Dystonia
July 2025
Movement Disorders Center, Department of Neurology, University Hospitals Cleveland Medical Center, Cleveland, OH, United States.
Introduction: Pain is a common symptom of cervical dystonia (CD). The mainstay of treatment of CD is botulinum toxin, which is known to have benefits in relieving pain. We aimed to characterize the locations of pain in patients with CD, and to assess what factors may predict pain reduction following botulinum toxin injection.
View Article and Find Full Text PDFAssessing Congenital Muscular Torticollis Using Myotonometry: A Novel Approach.
J Musculoskelet Neuronal Interact
September 2025
Istanbul Okan University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, İstanbul, Turkey.
Objective: This study aimed to evaluate sternocleidomastoid (SCM) muscle properties in infants with Congenital Muscular Torticollis (CMT) using myotonometry and determine its sensitivity to changes following physiotherapy.
Methods: Twenty-five infants (0-12 months) diagnosed with CMT participated in this study from May 2023 to February 2024. They underwent an 8-week physiotherapy program.
Emerging Highly Pathogenic Avian Influenza H5N1 Clade 2.3.4.4b Causes Neurological Disease and Mortality in Scavenging Ducks in Bangladesh.
Vet Sci
July 2025
Department of Pathology, Faculty of Veterinary Science, Bangladesh Agricultural University, Mymensingh 2202, Bangladesh.
Scavenging domestic ducks significantly contribute to the transmission and maintenance of highly pathogenic H5N1 clade 2.3.4.
View Article and Find Full Text PDFA 10-Year Review of the Efficacy of Cranial Remolding Orthosis Treatment and Factors That Influence Outcomes for Infants with Isolated Deformational Plagiocephaly.
Children (Basel)
August 2025
Cranial Technologies, Inc., Tempe, AZ 85284, USA.
Background/objectives: The purpose of this study was to examine the overall efficacy and treatment outcomes of CROs in the treatment of isolated deformational plagiocephaly and investigate the variables that influence treatment efficacy.
Methods: This was a 10-year retrospective review of N = 27, 990 infants with Isolated Deformational Plagiocephaly (IDP) who completed Cranial Remolding Orthosis (CRO) treatment between 3 and 18 months of age.
Results: There was a significant overall mean change in CVAI(S) of -3.